Goldman Comments on Verve Therapeutics (NASDAQ: VERV)The analyst comments "VERV announced positive initial Ph1b Heart-2 data from lead PCSK9 program ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE